Zhejiang Ausun Pharmaceutical (SHA:603229) will be able to produce and sell its imatinib mesylate tablets after receiving a drug registration certificate from the Chinese drug administration, according to a Shanghai bourse filing on Wednesday.
The drug is used as a treatment for chronic myeloid leukemia and gastrointestinal stromal tumors.
The pharmaceutical company invested 9.2 million yuan into the research and development of the drug.
The company's shares rose over 1% during midday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments